Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04549402
Other study ID # HeMirror
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date August 31, 2021
Est. completion date May 1, 2022

Study information

Verified date March 2022
Source Investigación en Hemofilia y Fisioterapia
Contact Rubén Cuesta-Barriuso, PhD
Phone +34 913146508
Email ruben.cuestab@gmail.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Background. The recurrence of hemarthrosis in patients with hemophilia favors the development of a progressive, degenerative intra-articular lesion (hemophilic arthropathy). Pain is one of the main clinical manifestations of this arthropathy. Objective. Assess the safety and efficacy of a pain intervention by visualizing movement using an augmented reality mobile application and immersive 360º video, regarding the frequency of bleeding and the improvement in pain perception and quality of life, joint condition , strength and functionality in patients with hemophilic arthropathy. Study design. Randomized, multicenter, single-blind clinical study. Method. 70 patients with hemophilia A and B will be recruited in this study. The patients will be recruited in 5 regions of Spain. The 8 dependent variables will be: frequency of bleeding (self-registration), pain (measured with the visual analog scale and pressure algometer, Tampa Scale of Kinesiophobia and Pain Catastrophizing Scale), quality of life (SF-12 scale), anxiety (questionnaire of Anxiety Status-Trait-STAI), joint status (Hemophilia Joint Health Score scale), muscle strength (dynamometer) and functionality (6-Minutes Walking test, Quick Disabilities of the arm, shoulder and hand). Three evaluations will be carried out: pre-treatment, post-treatment and after a follow-up period of 6 months. Expected results. To observe the efficacy of the visualization of movement in the characteristics of pain, and its implication in the functionality, joint state, muscular strength and the perception of quality of life in patients with hemophilic arthropathy.


Recruitment information / eligibility

Status Recruiting
Enrollment 70
Est. completion date May 1, 2022
Est. primary completion date February 1, 2022
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Male
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria: - Patients diagnosed with hemophilia A and B - Patients with a medical diagnosis of hemophilic arthropathy and pain - People over 18 years of age - Patients on prophylactic or on-demand treatment regimen with FVIII / FIX concentrates Exclusion Criteria: - Patients with neurological or cognitive disorders that impede understanding of the questionnaires - Pain free patients - Amputees, epileptics or patients with severe vision problems - Patients who are receiving Physiotherapy treatment at the time of the study - Patients who have not signed the informed consent document

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Mirror Therapy group
The intervention protocol will be carried out under the same environmental conditions and, as far as possible, on time. The intervention will last 4 weeks, with a periodicity of 7 weekly sessions. In total there will be 28 sessions lasting between 15 and 45 minutes depending on the number of joints affected.
Video group
The intervention protocol will be carried out under the same environmental conditions and, as far as possible, on time. The intervention will last 4 weeks, with a periodicity of 7 weekly sessions. In total there will be 28 sessions lasting between 15 and 45 minutes depending on the number of joints affected.

Locations

Country Name City State
Spain European University of Madrid Madrid

Sponsors (1)

Lead Sponsor Collaborator
Investigación en Hemofilia y Fisioterapia

Country where clinical trial is conducted

Spain, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change from baseline hemarthrosis after treatment and at 2 months A self-registration will be used to evaluate the frequency of bleeding, and thus the safety of the technique. This self-registration will be given to each patient at the beginning of the study and they must fill in the number of hemarthrosis and their main characteristics: date, origin (traumatic or spontaneous) and location (knee, ankle or elbow). The self-registration will be delivered to the evaluator in each of the study evaluations (post-treatment and follow-up). Screening visit, within the first seven days after treatment and after two months follow-up visit
Secondary Change from baseline joint pain after treatment and at 2 months The visual analog scale will be used to assess the perception of joint pain, being valued with a range of 0 to 10 points (from no pain to the maximum pain suffered or imaginable) in the joints evaluated Screening visit, within the first seven days after treatment and after two months follow-up visit
Secondary Change from baseline pressure pain threshold after treatment and at 2 months With a pressure algometer (model Wagner FPN100) we will measure the pressure pain threshold, at the joint level and at a distance (in another part of the body). This device measures in Newton / cm2 the pressure at which the subject perceives pain under pressure. A pressure will be made on the chosen point, which we will increase at an approximate speed of 50kPa / s until the patient warns us that the sensation begins to be painful. Hemophilic arthropathy will be assessed in the elbow (on the lateral epicondyle, in the C5-C6 joint and in the tibialis anterior muscle), knee (inner edge of the patella, and tibialis anterior and extensor carpi longus muscles) and ankle (lateral malleolus, L5 spinous process, and extensor carpi longus muscle). Screening visit, within the first seven days after treatment and after two months follow-up visit
Secondary Change from baseline muscle strength after treatment and at 2 months With a pressure dynamometer (microFET®2 Digital Handheld model) we will measure the strength of the biceps brachii, quadriceps and triceps surae. This device measures in Newton the force that the patient exerts in the requested muscular action. The higher the value, the greater the muscle strength. We will carry out the measurements bilaterally. The patient will be asked 4 maximum isometric contractions of 5 seconds, with a rest of 30 seconds between them, against the dynamometer located in the hand of the evaluator Screening visit, within the first seven days after treatment and after two months follow-up visit
Secondary Change from baseline electrical activity of the muscles after treatment and at 2 months Using surface electromyography (model SHIMMMER2, Shimmer, Ireland), we will evaluate the electrical activity of the musculature and its level of activation. The placement of the electrodes will be marked on the standing subjects, and they will be placed following the European recommendations for the use of the SEMG. A bipolar SEMG system will be used with circular electrodes 10 mm in diameter, 20 mm apart, placed longitudinally, in the direction of the fibers of the studied muscle, and with a remote reference electrode. Screening visit, within the first seven days after treatment and after two months follow-up visit
Secondary Change from baseline perception of quality of life after treatment and at 2 months Using the generic Short Form 12 (SF-12v2) scale, the perception of quality of life of the patients included in the study will be evaluated. This scale consists of 12 items and a range from 0 to 100 points (where a higher score indicates a better perception of quality of life). Screening visit, within the first seven days after treatment and after two months follow-up visit
Secondary Change from baseline perception of anxiety after treatment and at 2 months With the State-Trait Anxiety Inventory (STAI) scale, the perception of anxiety of the patients included in the study will be measured. The state and the anxiety trait of each subject are evaluated with a score of 0 to 30 points for each scale, where a higher score indicates a higher anxiety index in the trait or state. Screening visit, within the first seven days after treatment and after two months follow-up visit
Secondary Change from baseline kinesiophobia after treatment and at 2 months With the Tampa Scale of kinesiophobia (TSK-11SV) questionnaire, the fear of movement of the patients included in the study will be evaluated. It consists of 11 items. Its values have a range of 1 to 4 points, where the higher the score, the greater the fear of movement. Screening visit, within the first seven days after treatment and after two months follow-up visit
Secondary Change from baseline catastrophizing after treatment and at 2 months With the Pain catastrophizing scale questionnaire, the catastrophizing of patients with congenital coagulopathies will be measured. The scale, made up of 13 items, is assessed with a range of 0 to 4 points (lower score indicates less catastrophism). Screening visit, within the first seven days after treatment and after two months follow-up visit
Secondary Change from baseline joint status after treatment and at 2 months With the Hemophilia Joint Health Score scale, specific for its use in patients with hemophilia, the joint status of patients with hemophilic arthropathy will be evaluated. It evaluates 8 items: inflammation and duration of this, pain, muscle atrophy and strength, crackles, and loss of flexion and extension. It has a score of 0 (no joint damage) to 20 points (maximum joint damage) per joint (elbows, knees and ankles). A gait rating is added to the 120 points (range 0-4 points), the maximum rating on this scale being 124 points. Screening visit, within the first seven days after treatment and after two months follow-up visit
See also
  Status Clinical Trial Phase
Completed NCT02229331 - Biomechanical Determinants and Patterns Associated to the Pathophysiological Cascade of Ankle Arthropathy in Children With Haemophilia: Non-invasive In-vivo Measurement of Foot Joints in Children With Haemophilia During Gait.
Completed NCT02870114 - National Survey of People With Haemophilia in Portugal N/A
Recruiting NCT02197611 - Development of a Specific Measure for Assessing Adherence in Adult Patients With Hemophilia. N/A
Unknown status NCT02582450 - Validation of a Specific Measure for Assessment of Compliance With Treatment in Patients With Hemophilia N/A
Completed NCT05138224 - Prevalence of Autistic Spectrum Disorder (ASD) in Children With Haemophilia
Recruiting NCT03287999 - Inter Individual Variability in Initiation Pathway Activation and Regulation and Phenotypic Heterogeneity in Patients With Haemophilia A and B
Completed NCT02825667 - Effectiveness of the Myofascial Therapy in the Hemophilic Arthropathy of Ankle N/A
Completed NCT03818529 - ATHN 8: Previously Untreated Patients (PUPs) Matter Study
Completed NCT05108480 - Self-myofascial Release With Foam Roller in Patients With Hemophilic Knee Arthropathy N/A
Completed NCT02781233 - A Progressive Resistance Training Program in Patients With Haemophilia N/A
Active, not recruiting NCT02512211 - Validation of Questionnaires HAL and HEP N/A
Active, not recruiting NCT02581735 - Effectiveness of the uPatient Platform in Prophylactic Treatment in Hemophilia N/A
Not yet recruiting NCT01623960 - Quality of Life in Adult Patients With Severe Haemophilia in Turkey N/A
Recruiting NCT02191436 - Adherence to Treatment in Hemophilia N/A
Completed NCT03264014 - Combining Registry Data in Haemophilia: TARGET H N/A
Recruiting NCT02198430 - Multidisciplinary Evaluation of Patients With Hemophilia N/A
Not yet recruiting NCT06046235 - Virtual Evaluations of Joint Health Using Wearable Sensors in Persons With Haemophilia (VESPA)
Completed NCT03529474 - Psychology and Physiotherapy Approach of Chronic Pain in Patients With Hemophilia N/A
Completed NCT05425888 - Functional and Proprioceptive Status in Patients With Hemophilic Ankle Arthropathy
Recruiting NCT03914209 - Extended Half-Life (EHL) Clotting Factor for Improving the Musculoskeletal Health of Patients With Hemophilia